About Shaperon
Shaperon is a company based in Seoul (South Korea) founded in 2008 by Seung Yong Seong. The company has 54 employees as of December 31, 2024. Shaperon operates in a competitive market with competitors including Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Revance Therapeutics and Alpine Immune Sciences, among others.
- Headquarter Seoul, South Korea
- Employees 54 as on 31 Dec, 2024
- Founders Seung Yong Seong
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Shaperon Inc.
-
Annual Revenue
$12 K (USD)-91.77as on Dec 31, 2024
-
Net Profit
-$10.1 M (USD)-20.15as on Dec 31, 2024
-
EBITDA
-$9.46 M (USD)-11.78as on Dec 31, 2024
-
Latest Funding Round
$5.82 M (USD), Post-IPO
Apr 09, 2026
-
Investors
Mirae Asset
& 4 more
-
Employee Count
54
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Shaperon
Shaperon is a publicly listed company on the KRX with ticker symbol 378800 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Shaperon
Investors in Shaperon
Shaperon has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Mirae Asset, Daishin Securities and Samsung Securities.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Shaperon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Shaperon
Investment portfolio details for Shaperon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Shaperon
Detailed financials for Shaperon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Shaperon Comparisons
Peer comparison for Shaperon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Shaperon
Shaperon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Revance Therapeutics and Alpine Immune Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| Locked | Locked | Locked |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
|
Detailed competitors of Shaperon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Shaperon
Complete news archive for Shaperon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Shaperon
Shaperon was founded in 2008 and raised its 1st funding round 17 years after it was founded.
Shaperon is headquartered in Seoul, South Korea.
Seung Yong Seong is the current CEO of Shaperon. They have also founded this company.
As of Dec 31, 2024, the latest employee count at Shaperon is 54.
Annual revenue of Shaperon is $12K as on Dec 31, 2024.
Shaperon is engaged in business activities that are not detailed on the website. No specific information regarding sectors, solutions, or operational focus is provided. Further details about the companys scope and offerings are unavailable from the given content.
Shaperon's top competitors include Revance Therapeutics, Ironwood Pharma and Escient Pharmaceuticals.
Yes, Shaperon is publicly traded on KRX under the ticker symbol 378800.
Shaperon has 5 investors. Key investors include Mirae Asset, Daishin Securities, Samsung Securities, Korea Investment Holdings, and KB Securities.
The ticker symbol of Shaperon is 378800 on KRX.